Tag: Quantum BioPharma Ltd.

Sector Insights

December 1, 2025 • Views: 8

W5’s National Investigation Spotlights Quantum BioPharma’s Allegations of Stock Market Manipulation

Client News & Interviews

November 11, 2025 • Views: 3

Quantum BioPharma Cuts Liabilities in Half, Boosts Equity 275%, and Strengthens Path to Phase 2 MS Trial

Sector Insights

October 31, 2025 • Views: 3

Quantum BioPharma Launches USD $7 Million Reward Program for Proof of Market Manipulation

Client News & Interviews

October 29, 2025 • Views: 5

The Critical Role of the Myelin Sheath – And How Quantum BioPharma Is Advancing the Next Frontier in MS Neuroprotection

Client News & Interviews

August 18, 2025 • Views: 2

Quantum BioPharma’s Year of Execution: Clinical Momentum, Platform Progress, and a Stronger Balance Sheet

Client News & Interviews

July 3, 2025 • Views: 3

Lucid-MS: A New Approach in Quantum BioPharma’s Mission to Repair MS-Related Nerve Damage

Sector Insights

June 27, 2025 • Views: 3

Quantum BioPharma Confronts Extreme Short Pressure Amid Market Imbalances as Borrow Fees Surge Beyond 437%

Sector Insights

May 15, 2025 • Views: 9

Quantum BioPharma’s $700 Million Lawsuit Highlights Ongoing Concerns Over Market Manipulation

Client News & Interviews

April 22, 2025 • Views: 3

Quantum BioPharma’s Lucid-MS Offers New Hope For Multiple Sclerosis Treatment

Client News & Interviews

April 16, 2025 • Views: 7

Quantum BioPharma’s Secret Weapon: A Dual Engine of Clinical Innovation and Consumer Expansion

↑